Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Molecular Medicine
  4. Volume 24, Issue 11
  5. Article
Volume 24, Issue 11
  • ISSN: 1566-5240
  • E-ISSN:

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver condition worldwide. NAFLD is often associated with features of Metabolic Syndrome such as obesity and insulin resistance.

Methods

The current comprehensive meta-analysis was performed to evaluate the association between circulating Omentin levels and NAFLD. A systematic search in Scopus, Web of Science, PubMed, and Google Scholar databases was conducted to identify relevant studies up until 5th May 2022. The standard mean difference (SMD) values and 95% confidence intervals (CIs) were computed for the association of Omentin levels with NAFLD risk in a random effect model.

Results

The meta-analysis involved 6 case-control studies with a total of 371 cases and 269 controls. Pooled SMD showed no significant difference in serum Omentin between NAFLD and healthy groups (SMD= -0.047 and 95% CI -0.957_0.862 =0.91). Subgroup analysis based on sample size showed that the average Omentin levels were significantly higher in NAFLD patients in studies with sample size ≥70 (SMD=0.356 CI 0.056_0.655 =0.02).

Conclusion

Additional well-designed studies with more sample sizes are essential to clarify the potential role of Omentin as a risk marker of NAFLD.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmm/10.2174/1566524023666230913105910
2023-10-17
2024-11-26

  • From This Site

    /content/journals/cmm/10.2174/1566524023666230913105910
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. TsochatzisE.A. NewsomeP.N. Non-alcoholic fatty liver disease and the interface between primary and secondary care.Lancet Gastroenterol. Hepatol.20183750951710.1016/S2468‑1253(18)30077‑3 29893235
     [Google Scholar]
  2. BellentaniS. MarinoM. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD).Ann. Hepatol.20098Suppl. 1S4S8
     [Google Scholar]
  3. AdamsL.A. AnguloP. Recent concepts in non-alcoholic fatty liver disease.Diabet. Med.20052291129113310.1111/j.1464‑5491.2005.01748.x 16108837
     [Google Scholar]
  4. BekaertM. VerhelstX. GeertsA. LapauwB. CaldersP. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: A systematic review.Obes. Rev.2016171688010.1111/obr.12333 26597657
     [Google Scholar]
  5. BessoneF. Molecular pathways of nonalcoholic fatty liver disease development and progression.Cell. Mol. Life Sci.20197619912810.1007/s00018‑018‑2947‑0
     [Google Scholar]
  6. PierantonelliI. Svegliati-BaroniG. Nonalcoholic fatty liver disease: Basic pathogenetic mechanisms in the progression from NAFLD to NASH.Transplantation20191031e1e1310.1097/TP.0000000000002480 30300287
     [Google Scholar]
  7. CaoH. Adipocytokines in obesity and metabolic disease.J. Endocrinol.20142202T47T5910.1530/JOE‑13‑0339 24403378
     [Google Scholar]
  8. OuchiN. ParkerJ.L. LugusJ.J. WalshK. Adipokines in inflammation and metabolic disease.Nat. Rev. Immunol.2011112859710.1038/nri2921 21252989
     [Google Scholar]
  9. SchäfflerA. SchölmerichJ. BüchlerC. Mechanisms of Disease: Adipocytokines and visceral adipose tissue—emerging role in nonalcoholic fatty liver disease.Nat. Clin. Pract. Gastroenterol. Hepatol.20052627328010.1038/ncpgasthep0186 16265231
     [Google Scholar]
  10. JungU.J. ChoiM. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.Int. J. Mol. Sci.20141546184622310.3390/ijms15046184
     [Google Scholar]
  11. FernsG.A. A meta-analysis of the relationship between serums metrnl-like protein/subfatin and risk of type 2 diabetes mellitus and coronary artery disease.Arch. Physiol. Biochem.2021202117
     [Google Scholar]
  12. PolyzosS.A. KountourasJ. MantzorosC.S. Adipokines in nonalcoholic fatty liver disease.Metabolism20166581062107910.1016/j.metabol.2015.11.006 26725002
     [Google Scholar]
  13. JaikanthC. 2013; Emergence of omentin as a pleiotropic adipocytokine.Exp. Clin. Endocrinol. Diabetes2013121737738310.1055/s‑0033‑1345123
     [Google Scholar]
  14. DoyleS.L. DonohoeC.L. LysaghtJ. ReynoldsJ.V. Visceral obesity, metabolic syndrome, insulin resistance and cancer.Proc. Nutr. Soc.201271118118910.1017/S002966511100320X 22051112
     [Google Scholar]
  15. YangR.Z. LeeM.J. HuH. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action.Am. J. Physiol. Endocrinol. Metab.20062906E1253E126110.1152/ajpendo.00572.2004 16531507
     [Google Scholar]
  16. AnsariM.H.K. GholamnejadM. MeghraziK. KhalkhaliH.R. Association of circulating omentin-1 level with lung cancer in smokers.Med. J. Islam. Repub. Iran201832133 30815428
     [Google Scholar]
  17. HalabisM. DziedzicM. WarchulinskaJ. Kaznowska-BystrykI. SolskiJ. Omentin - a new adipokine with many roles to play.Curr. Issues Pharm. Med. Sci.201528317618010.1515/cipms‑2015‑0067
     [Google Scholar]
  18. YamawakiH. KuramotoJ. KameshimaS. UsuiT. OkadaM. HaraY. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells.Biochem. Biophys. Res. Commun.2011408233934310.1016/j.bbrc.2011.04.039 21514279
     [Google Scholar]
  19. ChaiB. ZhengZ.H. LiaoX. The protective role of omentin-1 in IL-1β-induced chondrocyte senescence.Artif. Cells Nanomed. Biotechnol.202048181410.1080/21691401.2019.1699803 31852248
     [Google Scholar]
  20. ZhongX. LiX. LiuF. TanH. ShangD. Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway.Biochem. Biophys. Res. Commun.2012425240140610.1016/j.bbrc.2012.07.110 22842465
     [Google Scholar]
  21. SalokiN.K. The association of serum omentin-1 levels with biochemical parameters in patients with nonalcoholic fatty liver disease.Med. Sci.2021311122128
     [Google Scholar]
  22. RashadN. The association of serum omentin-1 levels with severity of nonalcoholic fatty liver disease in correlation with cardiovascular risk factors among Egyptian women.Med. J. Cairo Univ.201987June1783179110.21608/mjcu.2019.53966
     [Google Scholar]
  23. KnoblochK. YoonU. VogtP.M. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias.J. Craniomaxillofac. Surg.2011392919210.1016/j.jcms.2010.11.001 21145753
     [Google Scholar]
  24. StangA. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.Eur. J. Epidemiol.201025960360510.1007/s10654‑010‑9491‑z 20652370
     [Google Scholar]
  25. MontazerifarF. Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease.J. Res. Med. Sci.20172270
     [Google Scholar]
  26. WalugaM. KuklaM. KotulskiR. Omentin, vaspin and irisin in chronic liver diseases.J. Physiol. Pharmacol.2019702277285 31443090
     [Google Scholar]
  27. YilmazY. YonalO. KurtR. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease.Scand. J. Gastroenterol.2011461919710.3109/00365521.2010.516452 20809771
     [Google Scholar]
  28. BekaertM. OuwensD.M. HörbeltT. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.Obesity (Silver Spring)201624122544255210.1002/oby.21674 27768254
     [Google Scholar]
  29. ShibataR. OuchiN. TakahashiR. Omentin as a novel biomarker of metabolic risk factors.Diabetol. Metab. Syndr.2012413710.1186/1758‑5996‑4‑37 22835063
     [Google Scholar]
  30. LisI. PilarskiŁ. BogdańskiP. Omentin - a newly-discovered adipocytokine in insulin resistance pathogenesis.Pol. Merkur Lekarski2015392295660
     [Google Scholar]
  31. PanH.Y. GuoL. LiQ. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes.Diabetes Res. Clin. Pract.2010881293310.1016/j.diabres.2010.01.013 20129687
     [Google Scholar]
  32. TanB.K. AdyaR. FarhatullahS. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: Ex vivo and in vivo regulation of omentin-1 by insulin and glucose.Diabetes200857480180810.2337/db07‑0990 18174521
     [Google Scholar]
  33. LiuR. WangX. BuP. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome.Diabetes Res. Clin. Pract.2011931212510.1016/j.diabres.2011.03.001 21497934
     [Google Scholar]
  34. WalugaM. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.J. Physiol. Pharmacol.2017683363374
     [Google Scholar]
  35. MarraF. Modulation of liver fibrosis by adipokines.Dig. Dis.201129437137610.1159/000329799
     [Google Scholar]
  36. KuklaM. Potential Role of Leptin, Adiponectin and Three Novel Adipokines—Visfatin, Chemerin and Vaspin—in Chronic Hepatitis.Molecular Medicine20111713971410
     [Google Scholar]
  37. KuklaM. WalugaM. AdamekB. Omentin serum concentration and hepatic expression in chronic hepatitis C patients – together or apart?Pol. J. Pathol.20153323123810.5114/pjp.2015.54956 26619101
     [Google Scholar]
  38. KohanL. SafarpurM. AbdollahiH.J.M.B.R.C. Omentin-1 rs2274907 and resistin rs1862513 polymorphisms influence genetic susceptibility to nonalcoholic fatty liver disease.Mol. Biol. Res. Commun.2016511117
     [Google Scholar]
  39. YaykasliK.O. The frequency of omentin Val109Asp polymorphism and the serum level of omentin in patients with rheumatoid arthritis.Acta Medica Mediterranea201329521
     [Google Scholar]
  40. YörükÜ. Association of omentin Val109Asp polymorphism with coronary artery disease.Anadolu Kardiyol. Derg.201414651151410.5152/akd.2013.4932
     [Google Scholar]
  41. StojsavljevićS. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.World J. Gastroenterol.20142048180701809110.3748/wjg.v20.i48.18070
     [Google Scholar]
  42. Kłusek-OksiutaM. Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children.Ital. J. Pediatr.2014408410.1186/s13052‑014‑0084‑4
     [Google Scholar]
  43. ArjmandM-H. Clinical significance of circulating omentin levels in various malignant tumors: Evidence from a systematic review and meta-analysis.Cytokine202012515486910.1016/j.cyto.2019.154869
     [Google Scholar]
  44. Moreno-NavarreteJ.M. Circulating omentin concentration increases after weight loss.Nutr. Metab. (Lond.)201072710.1186/1743‑7075‑7‑27
     [Google Scholar]
  45. YinJ. Decreased levels of serum omentin-1 in patients with inflammatory bowel disease.Med. Sci. Monit.2015421118122
     [Google Scholar]
/content/journals/cmm/10.2174/1566524023666230913105910
Loading
The Association between Circulating Adipocytokine Omentin Levels and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
Current Molecular Medicine 24, 1374 (2024); https://doi.org/10.2174/1566524023666230913105910
/content/journals/cmm/10.2174/1566524023666230913105910
/content/journals/cmm/10.2174/1566524023666230913105910
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keyword(s): adipocytokines; adipokine; meta-analysis; metabolic syndrome; Nonalcoholic fatty liver disease; omentin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test